Bristol’s bad news is good for rivals: analysts By: MarketWatch August 02, 2012 at 17:51 PM EDT Bristol-Myers Squibb’s hepatitis C drug INX-189 might be a dud, but that may be a boon for rival drug developers, analysts say. Read More >> Related Stocks: Achison Inc Bristol-Myers Squibb Gilead Sciences Johnson & Johnson Merck & Co Vertex Pharmaceuticals